The Pharmaceutical Market: Belgium

Publication Date	October 2006
Publisher	Espicom
Product Type	Report
Pages	116
ISBN Number	not applicable
Product Code	ESP00221

Price

£595.00
approximately: $1,112 | €755

PDF

PRINT £595 ($1,112 | €755)

Order above formats by FAX

Summary

Per capita pharmaceutical expenditure in Belgium is comparatively high despite the fact that prices in Belgium are below average compared to the rest of Europe. Rising social security expenditure, however, has prompted the government to undertake increasingly severe measures to reduce drug expenditure. As a result, the Belgian pharmaceutical industry has been subjected to numerous cost containment measures in recent years.

Belgium is a relatively modest producer of pharmaceutical products, despite being a world leader in the production of vaccines. The majority of indigenous producers are small companies, and only a handful of multinationals have made Belgium a key manufacturing site. Many multinationals, however, use Belgium as an international distribution centre, meaning that import-export trade in pharmaceutical products far outweighs the value of the domestic market.

The generics market has been boosted by the loss of patent protection for high volume products such as omeprazole and simvastatin. However, moves to switch to a system of tendering for these molecules and other high volume off patent products, has called into question the future development of the generics industry. Despite government assurances that it means to provide greater support for innovative medicines, the existing reimbursement system and the Budget Ministry's right of veto regarding costly products can impede the introduction of new drugs.

These in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Content

Background Data

Geography
- Political overview
Economic Overview
Population
- Population Trends,
- Population by Region,
- Population by Province, July
- Population by Age Group,
- Projected Population by Age Group,
Demographic Indicators
- Demographic Indicators,
- Average Age of Mothers Giving Birth in Flanders,
Mortality
- Trends in Mortality by Leading Causes, 1994-1997 (%)
- Causes of Death,
Morbidity
- Percentage of Population Suffering from Long-Term Illnesses,
- Percentage of Population Suffering from Selected Long-Term Illnesses,
- Prevalence of Long Term Illnesses by Disorder in Males, 2004 (%)
- Prevalence of Long Term Illnesses by Disorder in Females, 2004 (%)
- Cardiovascular disorders
- Mental disorders
- Population Suffering from Mental Health Problems,
- Neurological disorders
- Respiratory disorders
- Cancer
- Incidence of Cancer by Principal Site,
- Musculoskeletal disorders
- HIV / AIDS, sexually transmitted diseases
- Incidence of Sexually Transmitted Diseases,
Belgium Background Data
Charts
- Map of Belgium
- Population by Age Group, 2005 (%)
- Chichester, West Sussex, PO20 2FS, United Kingdom

Healthcare System

Organisation & Administration
- Development of the Healthcare System
- Health Insurance
Health Expenditure
- Health Expenditure,
- Inami Health Expenditure, 1995-2005 (Million Euros)
- Inami Health Expenditure By Sector, 2001-2006 (Million Euros)
- Household Spending on Healthcare Products and Services, 1997-2001 (euros)
Hospital Services
- Hospital Services,
- Hospital Groups by Bedsize,
- Hospitals by Type & Region, Mid-year
- Non-Psychiatric Hospital Groups by Type and Province, Mid-year
- Non-Psychiatric Hospital Groups by Bedsize, Mid-year
- Beds in Non-Psychiatric Hospitals by Specialty and Region, Mid-year
- Beds in Non-Psychiatric Hospitals by Specialty and Hospital Type, Mid-year
- Hospital Facilities by Type of Hospital, 2001*
- Cardiac Facilities in Acute Hospitals,
- Neuro-surgery Facilities in Acute Hospitals,
- Imaging Facilities in Acute Hospitals,
- In VIVo Nuclear Medicine and Radiotherapy Facilities in Acute Hospitals,
- Hospital Activity
- Hospital Stays in Non-psychiatric Hospitals,
- Inpatient Stays in Acute Hospitals by Diagnostic Groups,
- Days Cases in Acute Hospitals by Diagnostic Groups,
- Hospitalisations,
- Most Frequent Causes of Hospitalisation in Men by Age Group, 2004 (% of hospitalisations)
- Most Frequent Causes of Hospitalisation in Women by Age Group, 2004 (% of hospitalisations)
- Public Hospitals
- Public Hospitals by Type & Region, Mid-year
- Beds in Public Non-Psychiatric Hospitals by Specialty, Mid-year
- Private Hospitals
- Private Hospitals by Type & Region, Mid-year
- Beds in Private Non-Psychiatric Hospitals by Specialty, Mid-year
Ambulatory Care
- GP Patient Contacts,
Belgium Healthcare System
Medical Personnel
- Medical Personnel,
- Doctors by Province & Region, 31/12/
- Doctors by Sex and Age, 31/12/
- Specialists by Sex and Specialty, 31/12/
- Chichester, West Sussex, PO20 2FS, United Kingdom
Accessing The Pharmaceutical
Market

Accessing The Pharmaceutical Market

Introduction
Regulatory Environment
- EU Regulatory Reforms
- Centralised procedure
- The EMEA
- Mutual recognition procedure
- Pharmaceutical Registration
- National Procedures
- Advertising
- Patent Protection & Intellectual Property Rights
- Supplementary Protection Certificates
- Pharmaceutical Pricing and Reimbursement
- EU Directive on the Transparency of Pricing and Reimbursement
- Pricing
- Reference Pricing
- Cost Control Policy
- Calculated Cost to the Drug Industry of Government Drug Containment Measures,
- Reimbursement
- Category A
- Category B
- Category C
- Distribution Channels
- Distributors
- Febelco
- Aprophar/ Alpha Repartition
- Pharma Belgium
- CERP Belgium
- Laboratoria Flandria
- Pharmacies
- Trade Fairs
Domestic Production
- Belgian Production of Pharmaceutical Products, 2000-2004 (euros 000)
- Trade Associations
- Domestic Producers
Belgium Accessing The Pharmaceutical Market
- Pharmaceutical Companies Manufacturing in Belgium
- AstraZeneca
- GlaxoSmithKline
- Janssen-Cilag/Janssen Pharmaceutica
- Janssen-Cilag/Janssen Pharmaceutica: Principal Products by Therapeutic Area
- Pfizer/Pharmacia
- Schering-Plough
- Laboratoires SMB
- Solvay Pharma
- Therabel
- Therabel Pharma S.A.: Principal Products
- UCB Pharma
- UCB Pharma: Major Products by Therapeutic Area
- Research & Development
- Janssen Research Foundation
- GlaxoSmithKline Biologicals
- UCB Pharma
- Eli Lilly
Directory
- Government Organisations
- Trade Associations
Charts
- Breakdown of Retail Price of Pharmaceuticals Sold in Pharmacies, 2003 (%)
- Average Share of Revenues from Pharmaceuticals Sold in Pharmacies, 2003 (%)
Inami Drug Expenditure According To Reimbursement Category, 2003 (%)
- Drugs Dispensed by Retail Pharmacies according to Reimbursement Category, 2003 (%)
- Belgian Wholesale Pharmacy Market by Principal Suppliers,
- Percentage Change in Pharmaceutical Output 2000-2004 (%)
- Pharma.be members by ownership, 2005 (%)
- Therabel Pharma S.A. Turnover by Therapeutic Class, 2001 (%)